|
|
|
References
Reverse Phase Protein Microarray Publications: 2. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn. 2007 Sep;7(5):625-33. Abstract 3. Espina V, Heiby M, Pierobon M, 4. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ,Qualman, S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein Pathway Mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Research. 2007;67(7):3431–4 Abstract 5. 5. Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, GoodmanZ, Liotta LA, Petricoin EF, and Younossi ZM. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology. 2007. April 1 Abstract 6. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK,Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA,Petricoin E, Liotta L, Lee JK, Weinstein JN. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. 2007 Mar;6(3):820-32 Abstract 7. Nijdam AJ, Ming-Cheng Cheng M, Geho DH, Fedele R, Herrmann P, Killian K, Espina V, Petricoin EF 3rd, Liotta LA, Ferrari M. Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials. 2006 Sep 20 [Epub ahead of print] Abstract 8. Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. Technology Insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006 May;3(5):256-68. Abstract 9. Gulmann C, Sheehan K, Kay E, Liotta L, Petricoin E 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol. 2006 Mar 3;208(5):595-606 Abstract 10. Davidson B, Espina V, Steinberg SM, Florenes VA, Liotta LA, Kristensen GB, Trope CG, Berner A, Kohn EC. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):791-9. Abstract 11. Gulmann C, Espina V, Petricoin E, Longo, DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL. Proteomic analysis of apoptotic pathways reveal prognostic factors in follicular lymphoma. Clinical Cancer Research 2005 Aug 15;11(16):5847-55. Abstract 12. Speer R, Wulfkuhle JD, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays for tissue-based analysis. Curr Opin Mol Ther. 2005 Jun;7(3):240-5. Abstract 13. Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta. 2005 Jul 24;357(2):180-3. Abstract 14. Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005 May 20;23(15):3614-21. Abstract 15. Geho D, Lahar N, Gurnani P, Huebschman M, Herrmann P, Espina V, Shi A, Wulfkuhle J, Garner H, Petricoin E 3rd, Liotta LA, Rosenblatt KP. Pegylated, Steptavidin-Conjugated Quantum Dots Are Effective Detection Elements for Reverse-Phase Protein Microarrays. Bioconjug Chem. 2005 May 18;16(3):559-566. Abstract 16. 16. Winters ME, Mehta AI, Petricoin EF 3rd, Kohn EC, Liotta LA. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res. 2005 May 1;65(9):3853-60 Abstract 17. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, ScAbstractr PE. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest. 2005 May 2;115(5):1163-1176. Abstract 18. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest. 2005;23(1):36-46. Abstract 19. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep. 2005 Feb-Apr;25(1-2):107-25. Abstract 21. Menard C, Susil RC, Choyke P, Coleman J, Grubb R, Gharib A, Krieger A, Guion P, Thomasson D, Ullman K, Gupta S, Espina V, Liotta L, Petricoin E, Fitchtinger G, Whitcomb LL, Atalar E, Coleman CN, Camphausen K. An Interventional Magnetic Resonance Imaging Technique for the Molecular Characterization of Intraprostatic Dynamic Contrast Enhancement. Mol Imaging. 2005 Jan;4(1):63-66. Abstract 22. Cowherd SM, Espina VA, Petricoin EF 3rd, Liotta LA. Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer. 2004 Dec;5(5):385-92. Abstract 23. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer. 2004 Nov;40(17):2623-32. Abstract 24. Rapkiewicz AV, Espina V, Petricoin EF 3rd, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer. 2004 Nov;40(17):2604-12. Abstract 25. Krieg RC, Knuechel R, Schiffmann E, Liotta LA, Petricoin EF 3rd, Herrmann PC. Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics. 2004 Sep;4(9):2789-95. Abstract 26. Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, Liotta LA. Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods. 2004 Jul;290(1-2):121-33. Abstract 27. Roberts E, Charboneau L, Espina V, Liotta L, Petricoin E, and Dreher K. Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure. J Toxicol Environ Health A. 2004 Jun 11;67(11):851-61. Abstract 28. Petricoin E, Wulfkuhle J, Espina V, and Liotta LA. Clinical proteomics: Revolutionizing disease detection and patient tailoring therapy. J Proteome Res. 2004 Mar-Apr;3(2):209-17. Abstract 29. Petricoin EF, and Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol Med. 2004 Feb;10(2):59-64. Abstract 30. Hasan RK, Wulfkuhle JD, Liotta LA, and Petricoin EF. Molecular technologies for personalized cancer management. JAMA. 2004 Apr 7;291(13):1644-5. Abstract 31. Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA and Jaffe ES. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. J Lab Invest. 2004 Feb;84(2):235-44. Abstract 32. Berman DM, Shih IM, Burke LA, Veenstra TD, Zhao Y, Conrads TP, Kwon SW, Hoang V, Yu LR, Zhou M, Kurman RJ, Petricoin EF, and Liotta LA. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). Proteomics. 2004 Mar;4(3):812-8. Abstract 33. Espina V, Dettloff KA, Cowherd S, Petricoin 3rd EF, and Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther. 2004 Jan;4(1):83-93. Abstract 34. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, and Petricoin EF 3rd. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003 Sep;3(9):1801-10. Abstract 35. Woodhouse EC, Fisher A, Bandle RW, Bryant-Greenwood B, Charboneau L, Petricoin EF 3rd, and Liotta LA. Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype. Proc Natl Acad Sci. 2003 Sep 30;100(20):11463-8. Abstract 36. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF, and Liotta LA. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol. 2003 532:59-68. Abstract 37. Espina V, Mehta AI, Winters ME, Wulfkuhle J, Petricoin EF, and Liotta LA. Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics. 2003 Nov;3(11):2091-100. Abstract 38. Grubb RL, Calvert VS, Paweletz CP, Phillips JL, Linehan WM, Gillespie JW, Emmert-Buck MR, Liotta L, and Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003 Nov;3(11):2142-6. Abstract 39. Wulfkuhle JD., Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, and Petricoin EF. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase microarrays. Proteomics. 2003 Nov;3(11):2085-90. Abstract 40. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Munson PJ, Petricoin EF, Liotta LA, and Weinstein JN. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Research. 2003 Sep 1;63(17):5243-50. Abstract 41. S Nishizuka, L Charboneau, L Young, S Major, WC. Reinhold, M Waltham, H Kouros-Mehr, KJ. Bussey, JK. Lee, PJ. Munson, EF. Petricoin III, LA. Liotta, and JN. Weinstein. Proteomic profiling of the NCI60 cancer cell lines using new high-density ‘reverse-phase’ lysate microarrays. Proc. Natl Acad Sci. 2003 Nov 25;100(24):14229-34. Abstract 42. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, and Petricoin EF. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003 Sep;3(9):1801-10. Abstract 43. Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF 3rd, Staudt LM, Thompson TE, Yang JC. Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol. 2003 May;1(5):302-6. Abstract 44. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, and Petricoin EF. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell. 2003 Apr;3(4):317-25. Abstract 45. Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., and Liotta, L.A. Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev. Drug Disc. 2002 Sep;1(9):683-95. Abstract 46. Charboneau L, Scott H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA, and Paweletz CP. Technique review: Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002 Oct;1(3):305-15. Abstract 47. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, and Petricoin EF 3rd. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics. 2002 Oct;1(10):1205-15. Abstract 48. Paweletz CP, Charboneau L, Roth MJ, Bichsel VE, Simone NL, Chen T, Han N, Gillespie JW, Emmert-Buck M, Petricoin EF, and Liotta LA. Reverse phase proteomic microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001 Apr 12;20(16):1981-9. Abstract 49. Paweletz CP, Liotta LA, and Petricoin EF. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology. 2001 Apr;57(4 Suppl 1):160-3. Abstract 50. Bichsel VE, Liotta LA, Petricoin EF 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling.Cancer J. 2001 Jan-Feb;7(1):69-78. Review. Abstract |
|
